Get a glimpse of what you can expect from the ILCA STW24
April is just around the corner and we’re excited to provide you with a sneak peek into what awaits you in Madrid on 26-27 April at the ILCA Single Topic Workshop. Read some insightful quotes from our esteemed speakers, offering a glimpse into the cutting-edge discussions and advancements that will enrich the workshop’s programme.
| Get your ticket |
Selection of second-line therapy HCC with Massimo Iavarone
26th April | 09.40 – 10.00 AM CET
“Over the last four years, the scenario of first-line treatment options for advanced hepatocellular carcinoma has been completely revolutionised first by the introduction of lenvantinib as an alternative to sorafenib and then by new therapeutic combinations involving checkpoint inhibitors (CI) with other (CI) or in combination with anti-VEGF or TKIs. This revolution represents an extraordinary benefit for patients but poses a challenge for clinicians, as there are no published clinical studies showing which drug should be used second-line after progression in patients treated with first-line immuno-based therapy. We will discuss what choices can be considered in the current period (clinical trials, standard of care, off-label options) and in the future based on the phase 3 second-line trials currently underway.”
Combining systemic therapy with radiotherapy in HCC with Laura Dawson
27th April | 09.20 – 09.40 AM CET
“There is a rapidly growing body of evidence demonstrating the benefits of radiation therapy for the treatment of hepatocellular carcinoma. Specifically in patients with macrovascular invasion, radiation therapy can lead to response with recanalization, even in patients with Vp3 and Vp4 vascular invasion. However, following radiation therapy alone, the time to response is delayed (e.g. months). Also, macrovascular invasion is a marker for increased risk of further microscopic invasion and occult cancer, providing rationale for the use of systemic therapy in the setting of macrovascular invasion. Systemic therapy is the standard of care treatment for such patients. However, outcomes are worse in patients with advanced (Vp3/4) macrovascular invasion, even with modern immunotherapy regimens. Thus, there is rationale for combined systemic therapy and radiation therapy. In this presentation, rationale for this combination, potential risks, and updates on the status of clinical trials of combined radiation therapy and systemic therapy will be reviewed.”